Company Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States.
The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.
It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus.
In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2.
It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics.
The company was incorporated in 1989 and is based in Carlsbad, California.
| Country | United States |
| Founded | 1989 |
| IPO Date | May 17, 1991 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 927 |
| CEO | Brett Monia |
Contact Details
Address: 2855 Gazelle Court Carlsbad, California 92010 United States | |
| Phone | 760 931 9200 |
| Website | ionispharma.com |
Stock Details
| Ticker Symbol | IONS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000874015 |
| CUSIP Number | 462222100 |
| ISIN Number | US4622221004 |
| Employer ID | 33-0336973 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Brett P. Monia Ph.D. | Founder, Chief Executive Officer and Director |
| Elizabeth L. Hougen M.A., M.B.A., M.S. | Executive Vice President of Finance and Chief Financial Officer |
| B. Lynne Parshall Esq., J.D. | Director |
| Dr. Richard S. Geary Ph.D. | Executive Vice President and Chief Development Officer |
| Dr. Eric E. Swayze Ph.D. | Executive Vice President of Research |
| Darren Gonzales | Chief Accounting Officer and Senior Vice President |
| Dr. C. Frank Bennett BSc, Ph.D. | Executive Vice President and Chief Scientific Officer |
| D. Wade Walke Ph.D. | Senior Vice President of Investor Relations |
| Patrick R. O'Neil Esq. | Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary |
| Hayley Soffer | Vice President of Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | 144/A | Filing |
| Nov 12, 2024 | 144 | Filing |
| Nov 12, 2024 | 144 | Filing |
| Nov 12, 2024 | 144 | Filing |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |
| Sep 12, 2024 | 8-K | Current Report |